Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 836 results for score

  1. Belimumab for treating active autoantibody-positive systemic lupus erythematosus (TA752)

    Evidence-based recommendations on belimumab (Benlysta) for treating active autoantibody-positive systemic lupus erythematosus.

    Technology appraisal guidance
    Published
    15 December 2021
    View recommendations

    Sections for TA752

  2. Deucravacitinib for treating moderate to severe plaque psoriasis (TA907)

    Evidence-based recommendations on deucravacitinib for treating moderate to severe plaque psoriasis in adults.

    Technology appraisal guidance
    Published
    28 June 2023
    View recommendations

    Sections for TA907

  3. Validation of clinical early warning scores in pre-hospital and emergency care settings:- Can early warning scores, for example NEWS (national early warning scores for adults) and PEWS (paediatric early warning score), be used to improve the detection of sepsis and facilitate prompt and appropriate clinical response in pre-hospital settings and in emergency departments?

    early warning scores in pre-hospital and emergency care settings:- Can early warning scores, for example NEWS (national...

    Research recommendation
    Published
    25 August 2016

  4. Human growth hormone (somatropin) in adults with growth hormone deficiency (TA64)

    Evidence-based recommendations on human growth hormone (somatropin; Genotropin, Humatrope, Norditropin, NutropinAq, Omnitrope, Saizen, Zomacton) for treating growth hormone deficiency in adults.

    Technology appraisal guidance
    Published
    27 August 2003
    View recommendations

    Sections for TA64

  5. Bimekizumab for treating moderate to severe plaque psoriasis (TA723)

    Evidence-based recommendations on bimekizumab (Bimzelx) for treating moderate to severe plaque psoriasis in adults.

    Technology appraisal guidance
    Published
    1 September 2021
    View recommendations

    Sections for TA723

  6. Alitretinoin for the treatment of severe chronic hand eczema (TA177)

    Evidence-based recommendations on alitretinoin (Toctino) for treating severe chronic hand eczema in adults.

    Technology appraisal guidance
    Published
    26 August 2009
    View recommendations

    Sections for TA177

  7. Apremilast for treating moderate to severe plaque psoriasis (TA419)

    Evidence-based recommendations on apremilast (Otezla) for treating moderate to severe plaque psoriasis in adults.

    Technology appraisal guidance
    Published
    23 November 2016
    View recommendations

    Sections for TA419

  8. What is the natural history of people with a Likert score on MRI of less than 3 without biopsy at long-term follow‑up?

    Question What is the natural history of people with a Likert score on MRI of less than 3 without biopsy at long-term follow‑up? Any...

    Research recommendation
    Published
    25 October 2019

  9. Infliximab for the treatment of adults with psoriasis (TA134)

    Evidence-based recommendations on infliximab for treating severe psoriasis in adults.

    Technology appraisal guidance
    Published
    23 January 2008
    View recommendations

    Sections for TA134

  10. Ixekizumab for treating moderate to severe plaque psoriasis (TA442)

    Evidence-based recommendations on ixekizumab (Taltz) for moderate to severe plaque psoriasis in adults.

    Technology appraisal guidance
    Published
    26 April 2017
    View recommendations

    Sections for TA442

  11. Brodalumab for treating moderate to severe plaque psoriasis (TA511)

    Evidence-based recommendations on brodalumab (Kyntheum) for treating moderate to severe plaque psoriasis in adults.

    Technology appraisal guidance
    Published
    21 March 2018
    View recommendations

    Sections for TA511

  12. Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (TA584)

    Evidence-based recommendations on atezolizumab (Tecentriq) with bevacizumab (Avastin), carboplatin and paclitaxel for metastatic non-squamous non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    5 June 2019
    View recommendations

    Sections for TA584

  13. Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban (TA697)

    Evidence-based recommendations on andexanet alfa (Ondexxya) for reversing anticoagulation form apixaban or rivaroxaban in adults with life-threatening or uncontrolled bleeding.

    Technology appraisal guidance
    Published
    12 May 2021
    View recommendations

    Sections for TA697

  14. Ambulight PDT for the treatment of non-melanoma skin cancer (MTG6)

    Evidence-based recommendations on Ambulight PDT for the treatment of non-melanoma skin cancer.

    Medical technologies guidance
    Published
    25 July 2011
    View recommendations

    Sections for MTG6

  15. Daridorexant for treating long-term insomnia (TA922)

    Evidence-based recommendations on daridorexant (QUVIVIQ) for treating long-term insomnia in adults.

    Technology appraisal guidance
    Published
    18 October 2023
    View recommendations

    Sections for TA922